参考文献
[1] Visseren F, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34):3227‑3337. DOI: 10.1093/eurheartj/ehab484.
[2] Ortiz A, Wanner C, Gansevoort R, et al. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association[J]. Nephrol Dial Transplant, 2023, 38(3):527‑531. DOI: 10.1093/ndt/gfac257.
[3] Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular‑kidney‑metabolic health: a presidential advisory from the American Heart Association[J]. Circulation, 2023, 148(20):1606‑1635. DOI: 10.1161/CIR.0000000000001184.
[4] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. kidney Int, 2013,3:1‑150. DOI: 10.1038/kisup.2012.73.
[5] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int, 2024, 105(4S):S117‑S314. DOI: 10.1016/j.kint.2023.10.018.
[6] 国家心血管病中心, 中国心血管健康与疾病报告编写组, 胡盛寿. 中国心血管健康与疾病报告2023概要[J]. 中国循环杂志, 2024, 39(7):625‑660. DOI: 10.3969/j.issn.1000‑3614.2024.07.001.
[7] Vallianou NG, Mitesh S, Gkogkou A, et al. Chronic kidney disease and cardiovascular disease: is there any relationship?[J]. Curr Cardiol Rev, 2019, 15(1):55‑63. DOI: 10.2174/1573403X14666180711124825.
[8] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990‑2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2020, 395(10225):709‑733. DOI: 10.1016/S0140‑6736(20)30045‑3.
[9] Wang X, Hao G, Chen L, et al. Hypertension‑mediated organ damage and established cardiovascular disease in patients with hypertension: the China Hypertension Survey, 2012‑2015[J]. J Hum Hypertens, 2022, 36(12):1092‑1098. DOI: 10.1038/s41371‑021‑00635‑z.
[10] Hong Z, Jiang Y, Liu P, et al. Association of microalbuminuria and adverse outcomes in hypertensive patients: a meta‑analysis[J]. Int Urol Nephrol, 2021, 53(11):2311‑2319. DOI: 10.1007/s11255‑021‑02795‑w.
[11] Díez J, Ortiz A. The need for a cardionephrology subspecialty[J]. Clin Kidney J, 2021, 14(6):1491‑1494. DOI: 10.1093/ckj/sfab054.
[12] Fox CS, Muntner P, Chen AY, et al. Use of evidence‑based therapies in short‑term outcomes of ST‑segment elevation myocardial infarction and non‑ST‑segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry[J]. Circulation, 2010, 121(3):357‑365. DOI: 10.1161/CIRCULATIONAHA.109.865352.
[13] Yandrapalli S, Christy J, Malik A, et al. Impact of acute and chronic kidney disease on heart failure hospitalizations after acute myocardial infarction[J]. Am J Cardiol, 2022,165:1‑11. DOI: 10.1016/j.amjcard.2021.10.041.
[14] Mok Y, Ballew SH, Sang Y, et al. Albuminuria as a predictor of cardiovascular outcomes in patients with acute myocardial infarction[J]. J Am Heart Assoc, 2019, 8(8):e010546. DOI: 10.1161/JAHA.118.010546.
[15] Jackson CE, Solomon SD, Gerstein HC, et al. Albuminuria in chronic heart failure: prevalence and prognostic importance[J]. Lancet, 2009, 374(9689):543‑550. DOI: 10.1016/S0140‑6736(09)61378‑7.
[16] Shuvy M, Zwas DR, Lotan C, et al. Albuminuria: Associated with heart failure severity and impaired clinical outcomes[J]. Can J Cardiol, 2020, 36(4):527‑534. DOI: 10.1016/j.cjca.2019.09.001.
[17] Liang W, Liu Q, Wang QY, et al. Albuminuria and dipstick proteinuria for predicting mortality in heart failure: A systematic review and meta‑analysis[J]. Front Cardiovasc Med, 2021,8:665831. DOI: 10.3389/fcvm.2021.665831.
[18] 张健, 张宇辉. 多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析[J]. 中国循环杂志, 2015, 30(5):413‑416. DOI: 10.3969/j.issn.1000‑3614.2015.05.002.
[19] Patel RB, Fonarow GC, Greene SJ, et al. Kidney function and outcomes in patients hospitalized with heart failure[J]. J Am Coll Cardiol, 2021, 78(4):330‑343. DOI: 10.1016/j.jacc.2021.05.002.
[20] Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta‑analysis[J]. Eur Heart J, 2014, 35(7):455‑469. DOI: 10.1093/eurheartj/eht386.
[21] 上海市肾内科临床质量控制中心专家组. 慢性肾脏病早期筛查、诊断及防治指南(2022年版)[J]. 中华肾脏病杂志, 2022, 38(5):453‑464. DOI: 10.3760/cma.j.cn441217‑20210819‑00067.
[22] 中华预防医学会肾脏病预防与控制专业委员会. 中国慢性肾脏病早期评价与管理指南[J]. 中华内科杂志, 2023, 62(8):902‑930. DOI: 10.3760/cma.j.cn112138‑ 20221013‑00755.
[23] Nelson RG, Grams ME, Ballew SH, et al. Development of risk prediction equations for incident chronic kidney disease[J]. JAMA, 2019, 322(21):2104‑2114. DOI: 10.1001/jama.2019.17379.
[24] Ikizler TA, Burrowes JD, Byham‑Gray LD, et al. KDOQI clinical practice guideline for nutrition in ckd: 2020 update[J]. Am J Kidney Dis, 2020, 76(3 Suppl 1):S1‑S107. DOI: 10.1053/j.ajkd.2020.05.006.
[25] Joshi S, McMacken M, Kalantar‑Zadeh K. Plant‑based diets for kidney disease: a guide for clinicians[J]. Am J Kidney Dis, 2021, 77(2):287‑296. DOI: 10.1053/j.ajkd.2020.10.003.
[26] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2020, 98(4S):S1‑S115. DOI: 10.1016/j.kint.2020.06.019.
[27] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 等. 中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1):24‑56. DOI: 10.3969/j.issn.1007‑ 5410.2019.01.002.
[28] Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure[J]. J Am Soc Nephrol, 2009, 20(5):933‑939. DOI: 10.1681/ASN.2008040402.
[29] Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure[J]. Am J Physiol, 1992, 262(6 Pt 1):E763‑E778. DOI: 10.1152/ajpendo.1992.262.6.E763.
[30] Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure[J]. N Engl J Med, 1999, 340(17):1321‑1328. DOI: 10.1056/NEJM199904293401704.
[31] Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanisms[J]. Int J Mol Sci, 2017, 18(8):1682. DOI: 10.3390/ijms18081682.
[32] Matsushita K, Ballew SH, Wang AY, et al. Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease[J]. Nat Rev Nephrol, 2022, 18(11):696‑707. DOI: 10.1038/s41581‑022‑00616‑6.
[33] Yu Z, Rebholz CM, Wong E, et al. Association between hypertension and kidney function decline: The Atherosclerosis Risk in Communities (ARIC) Study[J]. Am J Kidney Dis, 2019, 74(3):310‑319. DOI: 10.1053/j.ajkd.2019.02.015.
[34] Blood Pressure Lowering Treatment Trialists′ Collaboration, Ninomiya T, Perkovic V, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta‑analysis of randomised controlled trials[J]. BMJ, 2013, 347:f5680. DOI: 10.1136/bmj.f5680.
[35] Rigo D, Orias M. Hypertension and kidney disease progression[J]. Clin Nephrol, 2020, 93(1):103‑107. DOI: 10.5414/CNP92S118.
[36] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Hypertension, 2018, 71(6):1269‑1324. DOI: 10.1161/HYP.0000000000000066.
[37] Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease[J]. Kidney Int, 2021, 99(3S):S1‑S87. DOI: 10.1016/j.kint.2020.11.003.
[38] 中华医学会肾脏病学分会专家组. 中国慢性肾脏病患者高血压管理指南(2023年版)[J]. 中华肾脏病杂志, 2023, 39(1):48‑80. DOI: 10.3760/cma.j.cn441217‑20220630‑00650.
[39] 慢性肾脏病高血压管理共识专家组. 非透析和透析慢性肾脏病患者高血压管理的中国专家共识[J]. 中华内科杂志, 2023, 62(7):748‑774. DOI: 10.3760/cma.j.cn112138‑20220909‑00670.
[40] Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first‑in‑class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38(4):269‑275. DOI: 10.1038/hr.2015.1.
[41] Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin‑neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure[J]. Eur J Heart Fail, 2022, 24(9):1591‑1598. DOI: 10.1002/ejhf.2421.
[42] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension[J]. J Hypertens, 2018, 36(10):1953‑2041. DOI: 10.1097/HJH.0000000000001940.
[43] Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease[J]. Rev Endocr Metab Disord, 2017, 18(1):29‑40. DOI: 10.1007/s11154‑016‑9402‑z.
[44] Katsiki N, Mikhailidis DP, Banach M. Lipid‑lowering agents for concurrent cardiovascular and chronic kidney disease[J]. Expert Opin Pharmacother, 2019, 20(16):2007‑2017. DOI: 10.1080/14656566.2019.1649394.
[45] 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年)[J]. 中华心血管病杂志, 2023, 51(3):221‑255. DOI: 10.3760/cma.j.cn112148‑20230119‑00038.
[46] Zhang L, Long J, Jiang W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9):905‑906. DOI: 10.1056/NEJMc1602469.
[47] Bragg F, Holmes MV, Iona A, et al. Association between diabetes and cause‑specific mortality in rural and urban areas of China[J]. JAMA, 2017, 317(3):280‑289. DOI: 10.1001/jama.2016.19720.
[48] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease[J]. Kidney Int, 2022, 102(5S):S1‑S127. DOI: 10.1016/j.kint.2022.06.008.
[49] 中华医学会糖尿病学分会, 中华医学会内分泌学分会. 中国成人2型糖尿病合并心肾疾病患者降糖药物临床应用专家共识[J]. 中华糖尿病杂志, 2020, 12(6):369‑381. DOI: 10.3760/cma.j.cn115791‑20200419‑00233.
[50] 中华医学会糖尿病学分会微血管并发症学组. 中国糖尿病肾脏病防治指南(2021年版)[J]. 中华糖尿病杂志, 2021, 13(8):762‑784. DOI: 10.3760/cma.j.cn115791‑20210706‑00369.
[51] 中国慢性肾脏病患者合并高尿酸血症诊治共识专家组. 中国慢性肾脏病患者合并高尿酸血症诊治专家共识[J]. 中华肾脏病杂志, 2017, 33(6):463‑469. DOI: 10.3760/cma.j.issn.1001‑7097.2017.06.012.
[52] Hijmering ML, Stroes ES, Olijhoek J, et al. Sympathetic activation markedly reduces endothelium‑dependent, flow‑mediated vasodilation[J]. J Am Coll Cardiol, 2002, 39(4):683‑688. DOI: 10.1016/s0735‑1097(01)01786‑7.
[53] Grassi G, D′Arrigo G, Pisano A, et al. Sympathetic neural overdrive in congestive heart failure and its correlates: systematic reviews and meta‑analysis[J]. J Hypertens, 2019, 37(9):1746‑1756. DOI: 10.1097/HJH.0000000000002093.
[54] Zoccali C, Mallamaci F, Tripepi G, et al. Norepinephrine and concentric hypertrophy in patients with end‑stage renal disease[J]. Hypertension, 2002, 40(1):41‑46. DOI: 10.1161/01.hyp.0000022063.50739.60.
[55] Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end‑stage renal disease[J]. Circulation, 2002, 105(11):1354‑1359. DOI: 10.1161/hc1102.105261.
[56] Shlipak MG, Tummalapalli SL, Boulware LE, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2021, 99(1):34‑47. DOI: 10.1016/j.kint.2020.10.012.
[57] Silvariño R, Rios P, Baldovinos G, et al. Is chronic kidney disease progression influenced by the type of renin‑angiotensin‑system blocker used?[J]. Nephron, 2019, 143(2):100‑107. DOI: 10.1159/000500925.
[58] Xie X, Liu Y, Perkovic V, et al. Renin‑angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A bayesian network meta‑analysis of randomized clinical trials[J]. Am J Kidney Dis, 2016, 67(5):728‑741. DOI: 10.1053/j.ajkd.2015.10.011.
[59] Prasad N, Yadav AK, Kundu M, et al. Renin‑angiotensin blocker use is associated with improved cardiovascular mortality in Indian patients with mild‑moderate chronic kidney disease‑findings from the ICKD study[J]. Front Med (Lausanne), 2022,9:1060148. DOI: 10.3389/fmed.2022.1060148.
[60] Zhang Y, He D, Zhang W, et al. ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non‑dialysis chronic kidney disease stages 3‑5: a network meta‑analysis of randomised clinical trials[J]. Drugs, 2020, 80(8):797‑811. DOI: 10.1007/s40265‑020‑01290‑3.
[61] Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency[J]. N Engl J Med, 2006, 354(2):131‑140. DOI: 10.1056/NEJMoa053107.
[62] Hou FF, Xie D, Zhang X, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency[J]. J Am Soc Nephrol, 2007, 18(6):1889‑1898. DOI: 10.1681/ASN.2006121372.
[63] Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline[J]. Ann Intern Med, 2012, 156(8):570‑581. DOI: 10.7326/0003‑4819‑156‑8‑201204170‑00004.
[64] Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double‑blind, controlled trial[J]. Lancet, 2008, 372(9638):547‑553. DOI: 10.1016/S0140‑6736(08)61236‑2.
[65] Lin CC, Wu YT, Yang WC, et al. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin‑angiotensin system blockade[J]. PLoS One, 2017, 12(12):e0189126. DOI: 10.1371/journal.pone.0189126.
[66] Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control[J]. Nat Rev Cardiol, 2020, 17(12):761‑772. DOI: 10.1038/s41569‑020‑0406‑8.
[67] Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes[J]. N Engl J Med, 2016, 375(4):323‑334. DOI: 10.1056/NEJMoa1515920.
[68] Vallon V, Thomson SC. The tubular hypothesis of nephron filtration and diabetic kidney disease[J]. Nat Rev Nephrol, 2020, 16(6):317‑336. DOI: 10.1038/s41581‑020‑0256‑y.
[69] Herrington WG, Savarese G, Haynes R, et al. Cardiac, renal, and metabolic effects of sodium‑glucose co‑transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‑hoc task force on sodium‑glucose co‑transporter 2 inhibitors[J]. Eur J Heart Fail, 2021, 23(8):1260‑1275. DOI: 10.1002/ejhf.2286.
[70] Herrington WG, Preiss D, Haynes R, et al. The potential for improving cardio‑renal outcomes by sodium‑glucose co‑transporter‑2 inhibition in people with chronic kidney disease: a rationale for the EMPA‑KIDNEY study[J]. Clin Kidney J, 2018, 11(6):749‑761. DOI: 10.1093/ckj/sfy090.
[71] Heerspink H, Stefánsson BV, Correa‑Rotter R, et al. Dapagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2020, 383(15):1436‑1446. DOI: 10.1056/NEJMoa2024816.
[72] McMurray J, Wheeler DC, Stefánsson BV, et al. Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease[J]. Circulation, 2021, 143(5):438‑448. DOI: 10.1161/CIRCULATIONAHA.120.051675.
[73] Heerspink H, Sjöström CD, Jongs N, et al. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre‑specified analysis from the DAPA‑CKD randomized controlled trial[J]. Eur Heart J, 2021, 42(13):1216‑1227. DOI: 10.1093/eurheartj/ehab094.
[74] The EMPA‑KIDNEY Collaborative Group,Herrington WG, Staplin N, et al. Empagliflozin in patients with chronic kidney disease[J]. N Engl J Med, 2023, 388(2):117‑127. DOI: 10.1056/NEJMoa2204233.
[75] Jhund PS, Solomon SD, Docherty KF, et al. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA‑HF[J]. Circulation, 2021, 143(4):298‑309. DOI: 10.1161/CIRCULATIONAHA.120.050391.
[76] Inzucchi SE, Claggett BL, Vaduganathan M, et al. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double‑blind, randomised, placebo‑controlled trial[J]. Lancet Diabetes Endocrinol, 2022, 10(12):869‑881. DOI: 10.1016/S2213‑8587(22)00308‑4.
[77] Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR‑Reduced[J]. Circulation, 2021, 143(4):310‑321. DOI: 10.1161/CIRCULATIONAHA.120.051685.
[78] Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR‑Preserved Trial[J]. Circulation, 2021, 144(16):1284‑1294. DOI: 10.1161/CIRCULATIONAHA.121.056824.
[79] Ferreira JP, Zannad F, Butler J, et al. Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR‑Pooled[J]. JAMA Cardiol, 2022, 7(11):1148‑1159. DOI: 10.1001/jamacardio.2022.2924.
[80] Liu T, Li R, Wang X, et al. Benefits of SGLT2 inhibitors combining with renin‑angiotensin‑system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta‑analysis[J]. Med Clin (Barc), 2022, 159(2):65‑72. DOI: 10.1016/j.medcli.2021.09.031.
[81] Liew A, Lydia A, Matawaran BJ, et al. Practical considerations for the use of SGLT‑2 inhibitors in the Asia‑Pacific countries‑An expert consensus statement[J]. Nephrology (Carlton), 2023, 28(8):415‑424. DOI: 10.1111/nep.14167.
[82] Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta‑Analysis Cardio‑Renal Trialists′ Consortium. Impact of diabetes on the effects of sodium glucose co‑transporter‑2 inhibitors on kidney outcomes: collaborative meta‑analysis of large placebo‑controlled trials[J]. Lancet, 2022, 400(10365):1788‑1801. DOI: 10.1016/S0140‑6736(22)02074‑8.
[83] Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med, 2020, 383(23):2219‑2229. DOI: 10.1056/NEJMoa2025845.
[84] Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes[J]. N Engl J Med, 2021, 385(24):2252‑2263. DOI: 10.1056/NEJMoa2110956.
[85] Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial[J]. Am J Nephrol, 2019, 50(5):345‑356. DOI: 10.1159/000503712.
[86] Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes[J]. N Engl J Med, 2024, 391(2):109‑121. DOI: 10.1056/NEJMoa2403347.